IP Library Granted Patent US 10,398,644
Granted Patent B2
US 10,398,644 · App. 15/666,057 · Granted Sep 3, 2019

Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films

Inventors: Robert Steven Davidson (Woodland Hills, CA); Gary S. Kehoe (Glendale, AZ)
Assignee: CURE PHARMACEUTICAL CORPORATION
A61K9/0056A61K9/0051A61K9/7007A61K36/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,398,644
App. No.
15/666,057
Granted
Sep 3, 2019
Kind
B2
Abstract

A medicant composition is provided. The composition includes a film layer and a powder matrix layer. The powder matrix layer includes a medicant. The powder matrix layer is applied to the film layer by admixing particulate to form a powder matrix and by then applying the powder matrix to the film layer by any desired method. The composition of the powder matrix is varied to alter the dissolution rate of the medicant, the adhesion of the medicant composition, and other physical properties of the powder matrix. The powder matrix layer can be cured.

Claims (19)

1. An edible thin film, comprising:

a film layer comprising a first medicant, carrageenan, an alginate, tapioca starch, pullulan, pectin, gum arabic, maltodextrin, polysorbate, sodium saccharin, clove oil, cinnamon oil, Echinacea, vitamin E, slippery elm, and aloe vera; and

a powder matrix coating comprising a second medicant, wherein the powder matrix coating is present on at least one side of the film layer.

2. The edible thin film of claim 1 , wherein the carrageenan is present in an amount of 1.5%-3%, the alginate is present in an amount of 8%-12%, the tapioca starch is present in an amount of 18%-25%, the pullulan is present in an amount of 15%-25%, the pectin is present in an amount of 15%-25%, the gum arabic is present in an amount of 2%-4%, the maltodextrin is present in an amount of 4%-6%, the polysorbate is present in an amount of 0.075%-0.175%, the sodium saccharin is present in an amount of 0.1%-0.4%, the clove oil is present in an amount of 2%-7%, the cinnamon oil is present in an amount of 2%-7%, the Echinacea is present in an amount of 1%-3%, the vitamin E is present in an amount of 0.5%-2%, the slippery elm is present in an amount of 2%-6%, and the aloe vera is present in an amount of 1.5%-3.5%, each by weight of the film layer.

3. The edible thin film of claim 1 , wherein the film layer dissolves within thirty seconds of being placed in an oral cavity.

4. The edible thin film of claim 1 , wherein each medicant is independently selected from the group consisting of anti-inflammatory steroids, anti-inflammatory anodynes, anti-inflammatory enzymes, antihistamine agents, oral sterilizing agents, antibiotics, chemically therapeutic agents, cardiac strengthening agents, blood vein dilating agents, local narcotic agents, cough curing agents, sore throat and mouth treatment agents, periodontal disease treatment agents, digesting organ curing agents, anti-diabetic agents, other enzymes, blood pressure depressing agents, tranquilizers, styptic agents, sexual hormones, agents for curing virulent carcinoma and agents for curing ulcers.

5. The edible thin film of claim 1 , wherein the edible thin film is bi-laminate mucoadhesive.

6. The edible thin film of claim 1 , wherein the thickness of the film layer is 0.01 mm to 3.00 mm.

7. The edible thin film of claim 1 , wherein the thickness of the film layer is 0.03 mm to 1.00 mm.

8. The edible thin film of claim 1 , wherein the thickness of the powder matrix coating is in the range of 5 μm to 3.00 mm.

9. The edible thin film of claim 1 , wherein the thickness of the powder matrix coating is in the range of 0.01 mm to 1.00 mm.

10. The edible thin film of claim 1 , configured to be placed in and to dissolve or otherwise disassociate in the mouth.

11. The edible thin film of claim 1 , configured for delivering a medicant in an oral cavity.

12. The edible thin film of claim 1 , configured to absorb at least four times its weight of water, saliva, or another aqueous solution, within a period of time from five seconds to fifteen minutes.

13. The edible thin film of claim 1 , configured to swell to at least three times its thickness in water, saliva, or another aqueous solution, within a period of time from five seconds to fifteen minutes.

14. The edible thin film of claim 1 , configured such that the powder matrix coating adheres to the mucosa or tissue of the mouth of a user, the mucosa or tissue of the nose of a user, the mucosa or tissue of the eyes of a user, the mucosa or tissue of the vagina of a user, the mucosa or tissue of the rectum of a user, or any combination thereof.

15. The edible thin film of claim 1 , wherein the powder matrix coating further comprises at least one of a bulking agent, a filler, a pigment, a flavoring agent, and a sweetener.

16. The edible thin film of claim 1 , comprising multiple film layers and each film layer independently comprises one or more natural water-soluble polymers, one or more synthetic water-soluble polymers, or a combination thereof.

17. The edible thin film of claim 1 , wherein the powder matrix coating further comprises a lipid, wax, polyvinyl alcohol (PVA), pectin, hydroxyethylcellulose, hydroxypropyl alkylcellulose, hydroxypropyl cellulose (HPC), methylcellulose (MC), carboxymethyl cellulose (CMC), ethylcellulose, microcrystalline cellulose (MCC), or a combination thereof.

Assignments (9)
LIEN Recorded Jan 28, 2025
From: CURE PHARMACEUTICAL, INC.
To: CUREX PHARMACEUTICAL MEXICO S.A.P.I. DE C.V.
Reel/Frame 070027/0201 →
CHANGE OF NAME Recorded Jul 17, 2023
From: TF TECH VENTURES, INC.
To: CURE PHARMACEUTICAL, INC.
Reel/Frame 064286/0450 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY NAME WHICH SHOULD READ TF TECH VENTURES, INC. AND NOT TF TECH VENTURES PREVIOUSLY RECORDED AT REEL: 060598 FRAME: 0016. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jul 12, 2023
From: CURE PHARMACEUTICAL CORPORATION
To: TF TECH VENTURES, INC.
Reel/Frame 064256/0361 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2022
From: CURE PHARMACEUTICAL CORPORATION
To: TF TECH VENTURES
Reel/Frame 060598/0016 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2022
From: CURE PHARMACEUTICAL HOLDING CORP.
To: CURE PHARMACEUTICAL CORPORATION
Reel/Frame 060516/0576 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 23, 2020
From: CURE PHARMACEUTICAL CORPORATION
To: CURE PHARMACEUTICAL HOLDING CORP.
Reel/Frame 054445/0736 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2017
From: INNOZEN, INC.
To: CURE PHARMACEUTICAL CORPORATION
Reel/Frame 043880/0284 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2017
From: ZENGEN, INC.
To: INNOZEN, INC.
Reel/Frame 043880/0203 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2017
From: DAVIDSON, ROBERT STEVEN; KEHOE, GARY S.
To: ZENGEN, INC.
Reel/Frame 043880/0114 →
Continuity (4)
Continuation 12251349 · Oct 14, 2008
Continuation 10706810 · Nov 12, 2003
Provisional Application 60426598 · Nov 14, 2002
Related Publication 20180015033A1 · Jan 18, 2018